NCT07705074Pas encore en recrutement
FAPI PET Imaging - An Exploratory Study
Résumé
This study is testing a new imaging tracer called \[18F\]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis. \[18F\]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well. People who join this study will get one injection of the tracer into a vein, then have one PET/CT or PET/MR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed. The study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.
Critères d'inclusion
• Written informed consent obtained and documented by the participant's signature. • Age ≥18 years at the time of consent. • Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol. • Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT/MRI) to allow comparative evaluation.
Critères d'exclusion
• Severe claustrophobia that would preclude PET imaging. • Inability to remain still for the duration of the PET/MR examination. • Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy. • Previous hypersensitivity reactions to radiotracer administration • Inability to understand the study information, for example due to language barriers. • Subjects incapable of judgment (e.g. individuals under legal or medical incapacity). • Participants scheduled for PET/MR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies.
Contacts
Les coordonnées de l'équipe de l'essai s'affichent sur demande.
Voir la fiche officielle de l'essai- Statut
- Pas encore en recrutement
- Phase
- Phase 1 · Phase 2
- Type d'étude
- Interventionnelle
- Pays
- Suisse
- Promoteur
- Martin Huellner(Autre)
- N° de protocole
- BASEC 2026-OO454
- Pathologies
- Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer (GC), Pancreatic Cancer, Adult, Urothelial Carcinoma (UC), Multiple Myeloma or Plasmacytoma, Mesothelioma, Hepatic Fibrosis, Endometriosis (Diagnosis), Lung Fibrosis, Neck Node Metastasis, Prostate Cancer (CRPC)
- Interventions
- Médicament
Traitements évalués
- [18F]FAPI-74 PET/CT
Collaborateurs
University Hospital, Zürich
Lieux · 5
- Baden, SuisseKantonsspital BadenRecrutement pas encore ouvert dans ce centre
- Geneva, SuisseHôpitaux Universitaires de Genève (HUG)Recrutement pas encore ouvert dans ce centre
- Lucerne, SuisseLuzerner KantonsspitalRecrutement pas encore ouvert dans ce centre
- Genolier, SuisseClinique de GenolierRecrutement pas encore ouvert dans ce centre
- Zurich, SuisseDepartment for Nuclear Medicine, University Hospital ZurichRecrutement pas encore ouvert dans ce centre
Au total, dans le monde, les 5 centres listés au registre sont prévus ; le recrutement n'est pas encore ouvert.
Statut par centre selon le registre ClinicalTrials.gov (dernière mise à jour publiée : 15 juillet 2026).
Ce statut peut avoir changé et ne dit rien de votre éligibilité : avant toute démarche, vérifiez avec votre oncologue ou le centre.
Autres identifiants
- BASEC 2026-OO454 · autre identifiant
Voir aussi
Autres versions
Ces résultats sont indicatifs et ne remplacent pas un avis médical — à discuter avec votre médecin.